cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2025-40-3-28-35cardiotomsk-2818Research ArticleОБЗОРЫREVIEWSЗначение фактора роста фибробластов 21 в норме и патологииThe value of fibroblast growth factor 21 in health and pathologyhttps://orcid.org/0000-0001-8010-6777АхвердянЮ. Р.AkhverdyanYu. R.

Ахвердян Юрий Рубенович - канд. мед. наук, старший научный сотрудник, лаборатория методов лечения и профилактики заболеваний суставов, НИИ КиЭР им. А.Б. Зборовского; доцент, кафедра клинической лабораторной диагностики, ВолгГМУ Минздрава России.

400138, Волгоград, ул. Землячки, 76; 400131, Волгоград, пл. Павших борцов, 1

Yury R. Akhverdyan, Cand. Sci. (Med.), Senior Research Scientist, Laboratory of Methods for the Treatment and Prevention of Joint Diseases, A.B. Zborovsky RICER; Associate Professor, Department of Clinical Laboratory Diagnostics, VolgSMU.

76, Zemlyatchky str., Volgograd, 400138; 2, 1, Pavshikh Bortsov squ., Volgograd, 400131

doctor_2001@mail.ruhttps://orcid.org/0000-0002-8799-2991ПапичевЕ. В.PapichevE. V.

Папичев Евгений Васильевич - канд. мед. наук, научный сотрудник, лаборатория методов лечения и профилактики заболеваний суставов, НИИ КиЭР им. А.Б. Зборовского; доцент, кафедра клинической лабораторной диагностики, ВолгГМУ Минздрава России.

400138, Волгоград, ул. Землячки, 76; 400131, Волгоград, пл. Павших борцов, 1

Evgeny V. Papichev - Cand. Sci. (Med.), Research Scientist, A.B. Zborovsky RICER; Associate Professor, Department of Clinical Laboratory Diagnostics, VolgSMU.

76, Zemlyatchky str., Volgograd, 400138; 2, 1, Pavshikh Bortsov squ., Volgograd, 400131

e_papichev@mail.ruhttps://orcid.org/0000-0002-8864-9570ЗаводовскийБ. В.ZavodovskyB. V.

Заводовский Борис Валерьевич - д-р мед. наук, заместитель директора по научным вопросам, НИИ КиЭР им. А.Б. Зборовского; заведующий кафедрой клинической лабораторной диагностики, ВолгГМУ Минздрава России.

400138, Волгоград, ул. Землячки, 76; 400131, Волгоград, пл. Павших борцов, 1

Boris V. Zavodovsky - Dr. Sci. (Med.), Professor, Head of Laboratory of Methods for the Treatment and Prevention of Joint Diseases, A.B. Zborovsky RICER, Head of the Department of Clinical Laboratory Diagnostics, VolgSMU.

76, Zemlyatchky str., Volgograd, 400138; 2, 1, Pavshikh Bortsov squ., Volgograd, 400131

pebma@pebma.ruhttps://orcid.org/0000-0002-3022-4166ПоляковаЮ. В.PolyakovaYu. V.

Полякова Юлия Васильевна - канд. мед. наук, научный сотрудник, НИИ КиЭР им. А.Б. Зборовского.

400138, Волгоград, ул. Землячки, 76

Julia V. Polyakova - Cand. Sci. (Med.), Research Scientist, A.B. Zborovsky RICER.

76, Zemlyatchky str., Volgograd, 400138

jpolyakova@yandex.ruhttps://orcid.org/0000-0002-0965-6060СивордоваЛ. Е.SeewordovaL. E.

Сивордова Лариса Евгеньевна - канд. мед. наук, ведущий научный сотрудник, лаборатория методов лечения и профилактики заболеваний суставов, НИИ КиЭР им. А.Б. Зборовского.

400138, Волгоград, ул. Землячки, 76

Larisa E. Seewordova - Cand. Sci. (Med.), Leading Research Scientist, A.B. Zborovsky RICER.

76, Zemlyatchky str., Volgograd, 400138

seeword@mail.ruhttps://orcid.org/0009-0001-5028-5409РожковаЕ. С.RozhkovaE. S.

Рожкова Екатерина Сергеевна - ассистент, кафедра клинической лабораторной диагностики, ВолгГМУ Минздрава России.

400131, Волгоград, пл. Павших борцов, 1

Ekaterina S. Rozhkova - Assistant, Department of Clinical Laboratory Diagnostics, VolgSMU.

2, 1, Pavshikh Bortsov squ., Volgograd, 400131

Научно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. Зборовского (НИИ КиЭР им. А.Б. Зборовского); Волгоградский государственный медицинский университет Министерства здравоохранения Российской Федерации (ВолгГМУ Минздрава России)РоссияA.B. Zborovsky Research Institute of Clinical and Experimental Rheumatology (A.B. Zborovsky RICER); Volgograd State Medical University of the Ministry of Health of the Russian Federation (VolgSMU)Russian FederationНаучно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. Зборовского (НИИ КиЭР им. А.Б. Зборовского)РоссияA.B. Zborovsky Research Institute of Clinical and Experimental Rheumatology (A.B. Zborovsky RICER)Russian FederationВолгоградский государственный медицинский университет Министерства здравоохранения Российской Федерации (ВолгГМУ Минздрава России)РоссияVolgograd State Medical University of the Ministry of Health of the Russian Federation (VolgSMU)Russian Federation2025051020254032835Copyright © Ахвердян Ю.Р., Папичев Е.В., Заводовский Б.В., Полякова Ю.В., Сивордова Л.Е., Рожкова Е.С., 20252025Ахвердян Ю.Р., Папичев Е.В., Заводовский Б.В., Полякова Ю.В., Сивордова Л.Е., Рожкова Е.С.Akhverdyan Y.R., Papichev E.V., Zavodovsky B.V., Polyakova Y.V., Seewordova L.E., Rozhkova E.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/2818

В статье приведены современные представления о роли фактора роста фибробластов 21 (FGF21) как у лабораторных животных, так и у людей в регуляции углеводного и липидного обмена, а также его вкладе в развитие системного воспаления при ревматоидном артрите (РА). Рассмотрена классификация семейства факторов роста фибробластов, регуляция экспрессии и рецепторный аппарат. Отмечены положительные эффекты FGF21 в виде нормализации углеводного и липидного обмена, массы тела. Приведены факты о применении препаратов аналогов FGF21 в качестве терапевтического средства для лечения метаболических осложнений, таких как диабет и жировая болезнь печени. В то же время приведены данные о связи повышенного уровня FGF21 в сыворотке крови с целым рядом патологических состояний, таких как сахарный диабет 2-го типа, ишемическая болезнь сердца, ожирение, неалкогольная жировая болезнь печени, терминальная стадия почечной недостаточности. Рассмотрены литературные данные о противоречивой роли FGF21 на фоне системного воспаления у пациентов с РА. С одной стороны, FGF21 может оказывать протективный эффект у пациентов с РА, с другой стороны, сывороточный FGF21 может рассматриваться как предиктор будущего снижения функционального состояния и потенциальный маркер прогрессирования системного воспаления у пациентов с РА. Дана оценка перспектив использования FGF21 в терапевтических целях.

The article presents current ideas about the role of fibroblast growth factor 21 (FGF21) in the regulation of carbohydrate and lipid metabolism, as well as its contribution to the development of systemic inflammation in rheumatoid arthritis, both in laboratory animals and in humans. The classification of the fibroblast growth factor family, regulation of expression and receptor apparatus is considered. Positive effects of FGF21 have been noted in the form of normalization of carbohydrate and lipid metabolism, body weight; drugs analogues of FGF21 have proven themselves well as a therapeutic agent for the treatment of metabolic complications such as diabetes and fatty liver disease. At the same time, data are provided on the connection between elevated levels of FGF21 in blood serum and a number of pathological conditions, such as type 2 diabetes mellitus, coronary heart disease, obesity, non-alcoholic fatty liver disease, and end-stage renal failure. The facts about the controversial role of FGF21 against the background of systemic inflammation in patients with rheumatoid arthritis (RA) are reviewed. On the one hand, FGF21 may have a protective effect in patients with RA; on the other hand, serum FGF21 can be considered as a predictor of future decline in functional status and a potential marker for the progression of systemic inflammation in patients with RA. The prospects for using FGF21 for therapeutic purposes are assessed.

фактор роста фибробластовFGF 21инсулинорезистентностьсахарный диабетревматоидный артритfibroblast growth factorFGF 21diabetesmetabolic syndromerheumatoid arthritisисследование выполнено без финансовой поддержки грантов, общественных, некоммерческих, коммерческих организаций и структурthe research was carried out without financial support from grants, public, non-profit, commercial organizations and structuresReferencesRai M., Demontis F. Systemic nutrient and stress signaling via myokines and myometabolites. Annu. Rev. Physiol. 2016;78:85–107. https://doi.org/10.1146/annurev-physiol-021115-105305.Rai M., Demontis F. Systemic nutrient and stress signaling via myokines and myometabolites. Annu. Rev. Physiol. 2016;78:85–107. https://doi.org/10.1146/annurev-physiol-021115-105305.Whitham M., Febbraio M.A. The ever-expanding myokinome: discovery challenges and therapeutic implications. Nat. Rev. Drug Discov. 2016;15:719–729. https://doi.org/10.1038/nrd.2016.153.Whitham M., Febbraio M.A. The ever-expanding myokinome: discovery challenges and therapeutic implications. Nat. Rev. Drug Discov. 2016;15:719–729. https://doi.org/10.1038/nrd.2016.153.Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol. 2001;2(3):reviews3005. https://doi.org/10.1186/gb-2001-2-3reviews3005.Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol. 2001;2(3):reviews3005. https://doi.org/10.1186/gb-2001-2-3reviews3005.Bon Durant L.D., Potthoff M.J. Fibroblast growth factor 21: A versatile regulator of metabolic homeostasis. Annu. Rev. Nutr. 2018;38:173–196. https://doi.org/10.1146/annurev-nutr-071816-064800.Bon Durant L.D., Potthoff M.J. Fibroblast growth factor 21: A versatile regulator of metabolic homeostasis. Annu. Rev. Nutr. 2018;38:173–196. https://doi.org/10.1146/annurev-nutr-071816-064800.Suntsova M.V., Buzdin A.A. Differences between human and chimpanzee genomes and their implications in gene expression, protein functions and biochemical properties of the two species. BMC Genomics. 2020;21(7):535. https://doi.org/10.1186/s12864-020-06962-8.Suntsova M.V., Buzdin A.A. Differences between human and chimpanzee genomes and their implications in gene expression, protein functions and biochemical properties of the two species. BMC Genomics. 2020;21(7):535. https://doi.org/10.1186/s12864-020-06962-8.Kim S.H., Kim K.H., Kim H.-K., Kim M.-J., Back S.H., Konishi M. et al. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia. 2015;58:809–818. https://doi.org/10.1007/s00125014-3475-6.Kim S.H., Kim K.H., Kim H.-K., Kim M.-J., Back S.H., Konishi M. et al. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia. 2015;58:809–818. https://doi.org/10.1007/s00125014-3475-6.Hirai Nomura K., Ikai R., Nakashima K.-I., Inoue M. Baicalein stimulates fibroblast growth factor 21 expression by up-regulating retinoic acid receptor-related orphan receptor α in C2C12 myotubes. Biomed. Pharmacother. 2019;109:503–510. https://doi.org/10.1016/j.biopha.2018.10.154.Hirai Nomura K., Ikai R., Nakashima K.-I., Inoue M. Baicalein stimulates fibroblast growth factor 21 expression by up-regulating retinoic acid receptor-related orphan receptor α in C2C12 myotubes. Biomed. Pharmacother. 2019;109:503–510. https://doi.org/10.1016/j.biopha.2018.10.154.Sugden M.C., Caton P.W., Holness M.J., Miller J.J. Receptors peroxisome proliferator-activated receptors. In: Jez J. (ed.) Encyclopedia of biological chemistry: 3rd edition. Elsevier, 2021:229–235.Sugden M.C., Caton P.W., Holness M.J., Miller J.J. Receptors peroxisome proliferator-activated receptors. In: Jez J. (ed.) Encyclopedia of biological chemistry: 3rd edition. Elsevier, 2021:229–235.Ogawa Y., Kurosu H., Yamamoto M., Nandi A., Rosenblatt K.P., Goetz R. et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA. 2007;104(18):7432–7437. https://doi.org/10.1073/pnas.0701600104.Ogawa Y., Kurosu H., Yamamoto M., Nandi A., Rosenblatt K.P., Goetz R. et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA. 2007;104(18):7432–7437. https://doi.org/10.1073/pnas.0701600104.Agrawal A., Parlee S., Perez-Tilve D., Li P., Pan J., Mroz P.A. et al. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. Mol. Metab. 2018;13:45–55. https://doi.org/10.1016/j.molmet.2018.05.003.Agrawal A., Parlee S., Perez-Tilve D., Li P., Pan J., Mroz P.A. et al. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity. Mol. Metab. 2018;13:45–55. https://doi.org/10.1016/j.molmet.2018.05.003.Ding X., Boney-Montoya J., Owen B.M., Bookout A.L., Coate K.C. et al. Beta Klotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012;16:387–393.Ding X., Boney-Montoya J., Owen B.M., Bookout A.L., Coate K.C. et al. Beta Klotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012;16:387–393.Krol E., Grant L., Shearer K., Wyse C., Moncur E. et al. Methionine restriction restores a younger metabolic phenotype in adult mice with alterations in fibroblast growth factor 21. Aging Cell. 2014;13(5):817–827. https://doi.org/10.1111/acel.12238.Krol E., Grant L., Shearer K., Wyse C., Moncur E. et al. Methionine restriction restores a younger metabolic phenotype in adult mice with alterations in fibroblast growth factor 21. Aging Cell. 2014;13(5):817–827. https://doi.org/10.1111/acel.12238.Fazeli P.K., Lun M., Kim S.M., Bredella M.A., Wright S., Zhang Y. et al. FGF21 and the late adaptive response to starvation in humans. J. Clin. Invest. 2015;125:4601–4611. https://doi.org/10.1172/JCI83349.Fazeli P.K., Lun M., Kim S.M., Bredella M.A., Wright S., Zhang Y. et al. FGF21 and the late adaptive response to starvation in humans. J. Clin. Invest. 2015;125:4601–4611. https://doi.org/10.1172/JCI83349.Patel R., Bookout A.L., Magomedova L., Owen B.M., Consiglio G.P., Shimizu M. et al. Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. Mol. Endocrinol. 2015;29:213–223. https://doi.org/10.1210/me.2014-1259.Patel R., Bookout A.L., Magomedova L., Owen B.M., Consiglio G.P., Shimizu M. et al. Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. Mol. Endocrinol. 2015;29:213–223. https://doi.org/10.1210/me.2014-1259.Veniant M.M., Hale C., Helmering J., Chen M.M., Stanislaus S., Busby J. et al. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One. 2012;7(7): e40164. https://doi.org/10.1371/journal.pone.0040164.Veniant M.M., Hale C., Helmering J., Chen M.M., Stanislaus S., Busby J. et al. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One. 2012;7(7): e40164. https://doi.org/10.1371/journal.pone.0040164.Fisher F.M., Maratos-Flier E. Understanding the physiology of FGF21. Annu. Rev. Physiol. 2016;78:223–241. https://doi.org/10.1146/annurevphysiol-021115-105339.Fisher F.M., Maratos-Flier E. Understanding the physiology of FGF21. Annu. Rev. Physiol. 2016;78:223–241. https://doi.org/10.1146/annurevphysiol-021115-105339.Tezze C., Romanello V., Sandri M. FGF21 as modulator of metabolism in health and disease. Front. Physiol. 2019;10:419. https://doi.org/10.3389/fphys.2019.00419.Tezze C., Romanello V., Sandri M. FGF21 as modulator of metabolism in health and disease. Front. Physiol. 2019;10:419. https://doi.org/10.3389/fphys.2019.00419.Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J. et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005;115:1627–1635. https://doi.org/10.1172/JCI23606.Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J. et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005;115:1627–1635. https://doi.org/10.1172/JCI23606.Inagaki T., Lin V.Y., Goetz R., Mohammadi M., Mangelsdorf D.J., Kliewer S.A. Inhibition of growth hormone signaling by the fastinginduced hormone FGF21. Cell Metab. 2008;8:77–83. https://doi.org/10.1016/j.cmet.2008.05.006.Inagaki T., Lin V.Y., Goetz R., Mohammadi M., Mangelsdorf D.J., Kliewer S.A. Inhibition of growth hormone signaling by the fastinginduced hormone FGF21. Cell Metab. 2008;8:77–83. https://doi.org/10.1016/j.cmet.2008.05.006.Johnson C.L., Weston J.Y., Chadi S.A., Fazio E.N., Huff M.W., Kharitonenkov A. et al. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology. 2009;137(5):1795–1804. https://doi.org/10.1053/j.gastro.2009.07.064.Johnson C.L., Weston J.Y., Chadi S.A., Fazio E.N., Huff M.W., Kharitonenkov A. et al. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology. 2009;137(5):1795–1804. https://doi.org/10.1053/j.gastro.2009.07.064.Jimenez V., Jambrina C., Casana E., Sacristan V., Muñoz S., Darriba S. et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol. Med. 2018;10(8):e8791. https://doi.org/10.15252/emmm.201708791.Jimenez V., Jambrina C., Casana E., Sacristan V., Muñoz S., Darriba S. et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol. Med. 2018;10(8):e8791. https://doi.org/10.15252/emmm.201708791.Shi Lu W., Hou Y., Fu K., Gan F., Liu J. Fibroblast growth factor ameliorates vascular calcification by inhibiting osteogenic transition in vitamin D3 plus nicotine-treated rats. Biochem. Biophys. Res. Commun. 2018;495(4):2448–2455. https://doi.org/10.1016/j.bbrc.2017.10.115.Shi Lu W., Hou Y., Fu K., Gan F., Liu J. Fibroblast growth factor ameliorates vascular calcification by inhibiting osteogenic transition in vitamin D3 plus nicotine-treated rats. Biochem. Biophys. Res. Commun. 2018;495(4):2448–2455. https://doi.org/10.1016/j.bbrc.2017.10.115.Staiger H., Keuper M., Berti L., Hrabe de Angelis M., Häring H.-U. Fibroblast growth factor 21-metabolic role in mice and men. Endocr. Rev. 2017;38(5):468–488. https://doi.org/10.1210/er.2017-00016.Staiger H., Keuper M., Berti L., Hrabe de Angelis M., Häring H.-U. Fibroblast growth factor 21-metabolic role in mice and men. Endocr. Rev. 2017;38(5):468–488. https://doi.org/10.1210/er.2017-00016.Прощай Г.А., Ворохобина Н.В., Загарских Е.Ю., Парцерняк С.А., Парцерняк А.С. Фактор роста фибробластов 21 и его влияние на метаболические процессы в организме человека. Вестник Санкт-Петербургского университета. 2018;13(1):38–45. https://doi.org/10.21638/11701/spbu11.2018.104.Partsernyak A.S. Fibroblast growth factor 21 and its influence on metabolic processes in the human body. Vestnik of Saint Petersburg University. 2018;13(1):38–45. https://doi.org/10.21638/11701/spbu11.2018.104.Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., DeFronzo R.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32:1542–1546. https://doi.org/10.2337/dc09-0684.Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., DeFronzo R.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32:1542–1546. https://doi.org/10.2337/dc09-0684.Zhang X., Yeung D.C.Y., Karpisek M., Stejskal D., Zhou Z.-G., Liu F. et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246–1253. https://doi.org/10.2337/db07-1476.Zhang X., Yeung D.C.Y., Karpisek M., Stejskal D., Zhou Z.-G., Liu F. et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246–1253. https://doi.org/10.2337/db07-1476.Tezze C., Romanello V., Desbats M.A., Fadini G.P., Albiero M., Favaro G. et al. Age-associated loss of opa1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence. Cell Metab. 2017;25(6):1374.e6–1389.e6. https://doi.org/10.1016/j.cmet.2017.04.021.Tezze C., Romanello V., Desbats M.A., Fadini G.P., Albiero M., Favaro G. et al. Age-associated loss of opa1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence. Cell Metab. 2017;25(6):1374.e6–1389.e6. https://doi.org/10.1016/j.cmet.2017.04.021.Kohara M., Masuda T., Shiizaki K., Akimoto T., Watanabe Y., Honma S. et al. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS One. 2017;12:e0178971. https://doi.org/10.1371/journal.pone.0178971.Kohara M., Masuda T., Shiizaki K., Akimoto T., Watanabe Y., Honma S. et al. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS One. 2017;12:e0178971. https://doi.org/10.1371/journal.pone.0178971.Lee C.H., Woo Y.C., Chow W.S., Cheung C.Y.Y., Fong C.H.Y., Yuen M.M.A. et al. Role of circulating fibroblast growth factor measurement in primary prevention of coronary heart disease among chinese patients with type 2 diabetes mellitus. J. Am. Heart Assoc. 2017;6:e005344. https://doi.org/10.1161/JAHA.116.005344.Lee C.H., Woo Y.C., Chow W.S., Cheung C.Y.Y., Fong C.H.Y., Yuen M.M.A. et al. Role of circulating fibroblast growth factor measurement in primary prevention of coronary heart disease among chinese patients with type 2 diabetes mellitus. J. Am. Heart Assoc. 2017;6:e005344. https://doi.org/10.1161/JAHA.116.005344.Conte M., Ostan R., Fabbri C., Santoro A., Guidarelli G., Vitale G. et al. Human aging and longevity are characterized by high levels of mitokines. J. Gerontol. A Biol. Sci. Med. Sci. 2019;74(5):600–607. https://doi.org/10.1093/gerona/gly153.Conte M., Ostan R., Fabbri C., Santoro A., Guidarelli G., Vitale G. et al. Human aging and longevity are characterized by high levels of mitokines. J. Gerontol. A Biol. Sci. Med. Sci. 2019;74(5):600–607. https://doi.org/10.1093/gerona/gly153.Samms R.J., Lewis J.E., Norton L., Stephens F.B., Gaffney C.J., Butterfield T. et al. FGF21 is an insulin-dependent postprandial hormone in adult humans. J. Clin. Endocrinol. Metab. 2017;102:3806–3813. https://doi.org/10.1210/jc.2017-01257.Samms R.J., Lewis J.E., Norton L., Stephens F.B., Gaffney C.J., Butterfield T. et al. FGF21 is an insulin-dependent postprandial hormone in adult humans. J. Clin. Endocrinol. Metab. 2017;102:3806–3813. https://doi.org/10.1210/jc.2017-01257.Besse-Patin A., Montastier E., Vinel C., Castan-Laurell I., Louche K., Dray C. et al. Effect of endurance training on skeletal muscle myokine expression in obese men: identification of apelin as a novel myokine. Int. J. Obes. 2014;38:707–713. https://doi.org/10.1038/ijo.2013.158.Besse-Patin A., Montastier E., Vinel C., Castan-Laurell I., Louche K., Dray C. et al. Effect of endurance training on skeletal muscle myokine expression in obese men: identification of apelin as a novel myokine. Int. J. Obes. 2014;38:707–713. https://doi.org/10.1038/ijo.2013.158.Parmar B., Lewis J.E., Samms R.J., Ebling F.J.P., Cheng C.C., Adams A.C. et al. Eccentric exercise increases circulating fibroblast activation protein α but not bioactive fibroblast growth factor 21 in healthy humans. Exp. Physiol. 2018;103(6):876–883. https://doi.org/10.1113/EP086669.Parmar B., Lewis J.E., Samms R.J., Ebling F.J.P., Cheng C.C., Adams A.C. et al. Eccentric exercise increases circulating fibroblast activation protein α but not bioactive fibroblast growth factor 21 in healthy humans. Exp. Physiol. 2018;103(6):876–883. https://doi.org/10.1113/EP086669.Liu Shi Z., Ji X., Zhang W., Luan J., Zahr T., Qiang L. Adipokines, adiposity, and atherosclerosis. Cell. Mol. Life Sci. 2022;79(5):272. https://doi.org/10.1007/s00018-022-04286-2.Liu Shi Z., Ji X., Zhang W., Luan J., Zahr T., Qiang L. Adipokines, adiposity, and atherosclerosis. Cell. Mol. Life Sci. 2022;79(5):272. https://doi.org/10.1007/s00018-022-04286-2.Opoku Y.K., Liu, Z., Liu, H. et al. Fibroblast growth factor-21 ameliorates rheumatoid arthritis by maintaining articular integrity. Int. J. Pept. Res. Ther. 2020;26:651–659. https://doi.org/10.1007/s10989-019-09872-w.Opoku Y.K., Liu, Z., Liu, H. et al. Fibroblast growth factor-21 ameliorates rheumatoid arthritis by maintaining articular integrity. Int. J. Pept. Res. Ther. 2020;26:651–659. https://doi.org/10.1007/s10989-019-09872-w.Gould P.W., Zemel B.S., Taratuta E.G., Baker J.F. Circulating fibroblast growth factor-21 levels in rheumatoid arthritis: associations with disease characteristics, body composition, and physical functioning. J. Rheumatol. 2021;48(4):504–512. https://doi.org/10.3899/jrheum.200673.Gould P.W., Zemel B.S., Taratuta E.G., Baker J.F. Circulating fibroblast growth factor-21 levels in rheumatoid arthritis: associations with disease characteristics, body composition, and physical functioning. J. Rheumatol. 2021;48(4):504–512. https://doi.org/10.3899/jrheum.200673.Yu D., Ye X., Che R., Wu Q., Qi J., Song L. et al. FGF21 exerts comparable pharmacological efficacy with Adalimumab in ameliorating collagen-induced rheumatoid arthritis by regulating systematic inflammatory response. Biomed. Pharmacother. 2017;89:751–760. https://doi.org/10.1016/j.biopha.2017.02.059.Yu D., Ye X., Che R., Wu Q., Qi J., Song L. et al. FGF21 exerts comparable pharmacological efficacy with Adalimumab in ameliorating collagen-induced rheumatoid arthritis by regulating systematic inflammatory response. Biomed. Pharmacother. 2017;89:751–760. https://doi.org/10.1016/j.biopha.2017.02.059.Yu Y., Li S., Liu Y., Tian G., Yuan Q., Bai F. et al. Fibroblast growth factor (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway. Int. Immunopharmacol. 2015;25(1):74–82. https://doi.org/10.1016/j.intimp.2015.01.005.Yu Y., Li S., Liu Y., Tian G., Yuan Q., Bai F. et al. Fibroblast growth factor (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway. Int. Immunopharmacol. 2015;25(1):74–82. https://doi.org/10.1016/j.intimp.2015.01.005.Kliewer S.A., Mangelsdorf D.J. A dozen years of discovery: Insights into the physiology and pharmacology of FGF21. Cell. Metab. 2019;29:246–253. https://doi.org/10.1016/j.cmet.2019.01.004.Kliewer S.A., Mangelsdorf D.J. A dozen years of discovery: Insights into the physiology and pharmacology of FGF21. Cell. Metab. 2019;29:246–253. https://doi.org/10.1016/j.cmet.2019.01.004.Lewis J.E., Ebling F.J.P., Samms R.J., Tsintzas K. Going back to the biology of FGF21: New insights. Trends Endocrinol. Metab. 2019;30:491–504. https://doi.org/10.1016/j.tem.2019.05.007.Lewis J.E., Ebling F.J.P., Samms R.J., Tsintzas K. Going back to the biology of FGF21: New insights. Trends Endocrinol. Metab. 2019;30:491–504. https://doi.org/10.1016/j.tem.2019.05.007.Gómez-Sámano M.Á., Grajales-Gómez M., Zuarth-Vázquez J.M., Navarro-Flores M.F., Martínez-Saavedra M., Juárez-León Ó.A. et al. Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol. 2017;11:335–341. https://doi.org/10.1016/j.redox.2016.12.024.Gómez-Sámano M.Á., Grajales-Gómez M., Zuarth-Vázquez J.M., Navarro-Flores M.F., Martínez-Saavedra M., Juárez-León Ó.A. et al. Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol. 2017;11:335–341. https://doi.org/10.1016/j.redox.2016.12.024.Wang Y., Ye J., Cao Y., Zhang R., Liu Y., Zhang S. et al. Increased serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and meta-analysis. Postgrad. Med. J. 2019;95:134–139. https://doi.org/10.1136/postgradmedj-2018-136002.Wang Y., Ye J., Cao Y., Zhang R., Liu Y., Zhang S. et al. Increased serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and meta-analysis. Postgrad. Med. J. 2019;95:134–139. https://doi.org/10.1136/postgradmedj-2018-136002.Franz K., Ost M., Otten L., Herpich C., Coleman V., Endres A. et al. Higher serum levels of fibroblast growth factor 21 in old patients with cachexia. Nutrition. 2019;63–64:81–86. https://doi.org/10.1016/j.nut.2018.11.004.Franz K., Ost M., Otten L., Herpich C., Coleman V., Endres A. et al. Higher serum levels of fibroblast growth factor 21 in old patients with cachexia. Nutrition. 2019;63–64:81–86. https://doi.org/10.1016/j.nut.2018.11.004.Praktiknjo M., Djayadi N., Mohr R., Schierwagen R., Bischoff J., Dold L. et al. Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. Liver Int. 2019;39:1514–1520. https://doi.org/10.1111/liv.14107.Praktiknjo M., Djayadi N., Mohr R., Schierwagen R., Bischoff J., Dold L. et al. Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. Liver Int. 2019;39:1514–1520. https://doi.org/10.1111/liv.14107.Ost Coleman V., Voigt A., van Schothorst E.M., Keipert S., van der Stelt I. et al. Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action. Mol. Metab. 2016;5(2):79–90. https://doi.org/10.1016/j.molmet.2015.11.002.Ost Coleman V., Voigt A., van Schothorst E.M., Keipert S., van der Stelt I. et al. Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action. Mol. Metab. 2016;5(2):79–90. https://doi.org/10.1016/j.molmet.2015.11.002.Sanyal A., Charles E.D., Neuschwander-Tetri B.A., Loomba R., Harrison S.A., Abdelmalek M.F. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebocontrolled, phase 2a trial. Lancet. 2019;392:2705–2717. https://doi.org/10.1016/S0140-6736(18)31785-9.Sanyal A., Charles E.D., Neuschwander-Tetri B.A., Loomba R., Harrison S.A., Abdelmalek M.F. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebocontrolled, phase 2a trial. Lancet. 2019;392:2705–2717. https://doi.org/10.1016/S0140-6736(18)31785-9.Kaufman A., Abuqayyas L., Denney W.S., Tillman E.J., Rolph T. AKR001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients. Cell Rep. Med. 2020;1(4):100057. https://doi.org/10.1016/j.xcrm.2020.100057.Kaufman A., Abuqayyas L., Denney W.S., Tillman E.J., Rolph T. AKR001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients. Cell Rep. Med. 2020;1(4):100057. https://doi.org/10.1016/j.xcrm.2020.100057.Charles E.D., Neuschwander-Tetri B.A., Pablo Frias J., Kundu S., Luo Y., Tirucherai G.S. et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: Results from a randomized phase 2 study. Obesity (Silver Spring). 2019;27(1):41–49. https://doi.org/10.1002/oby.22344.Charles E.D., Neuschwander-Tetri B.A., Pablo Frias J., Kundu S., Luo Y., Tirucherai G.S. et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: Results from a randomized phase 2 study. Obesity (Silver Spring). 2019;27(1):41–49. https://doi.org/10.1002/oby.22344.

The authors declare that there are no conflicts of interest present.